The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
 
Karen Anne Cadoo
Honoraria - OncLive
Consulting or Advisory Role - GlaxoSmithKline/Tesaro
Research Funding - AstraZeneca (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Fiona Simpkins
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Cara Amanda Mathews
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Seagen (Inst); Syros Pharmaceuticals (Inst); Tesaro/GSK (Inst)
 
Nashwa Kabil
Employment - AstraZeneca
 
James Bennett
Employment - AstraZeneca; AstraZeneca
 
Carol Aghajanian
Consulting or Advisory Role - Clovis Oncology; Eisai; Immunogen; Mersana; Roche; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)